Navigation Links
Next Safety, Inc.'s Innovative Drug Delivery System Will Replace,Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety, Inc. has identified basic scientific mechanisms that promise to revolutionize pulmonary drug delivery. This proprietary technology uses a stream of purified air to deliver medications deep into the pulmonary system. It is considered superior to other drug delivery systems because it rapidly administers aerosolized drugs to the lining of the lungs at previously unrealized efficiencies. The delivery technique has multiple applications across many therapeutic areas, such as asthma and nicotine replacement. Preliminary findings indicate that the Next Safety device delivers nicotine more efficiently than cigarettes, but without the negative effects of smoke.

According to estimates by the World Health Organizations smoking kills 5 million people globally each year. In 20 years, smoking will kill more than 10 million people per year. Half of the 1.3 billion smokers in the world today (650 million) will die from their habit.

"Our technology will save more lives than have been lost in all the wars in recorded history" - C. Eric Hunter, CEO and Founder of Next Safety, Inc.

"The fundamental nature of this development means that pulmonary delivery for a wide range of drug classes will be vastly improved or enabled," said Tom Stern, MD, assistant professor of medicine in the Department of Internal Medicine at Carolinas Medical Center and member of Next Safety's Medical Advisory Board. "To date laboratory data suggests applications such as childhood asthma or home delivery of medicines previously requiring an IV will be equally benefited. Although further testing is needed, this fundamental breakthrough may eventually be seen as important as the invention of the syringe."

"We've taken a fresh approach to pulmonary drug delivery," said Lyndell Duvall, director of technology & product development for Next Safety, Inc. "By obeying mother nature, and borrowing techniques and materials from the semiconductor industry, we are able to individually generate each droplet in an aerosol and dictate how it will behave before it is delivered to the patient."

The company is planning clinical testing under an IRB protocol that will include antibiotics, phenergan, albuterol, tobramycin, and morphine. The tests will be conducted in coordination with Carolinas Medical Center, located in Charlotte, NC. Early results should be available July 07'.

Next Safety is located in North Carolina, an area already known for leadership in technology and medicine. The company has leveraged this expertise to develop the worlds most advanced respirator technology and to advance the field of pulmonary medicine. Next Safety's bPure8000(TM) line of respirators provide higher protection against airborne viruses and fine particulate air pollution than any other respirator available globally. Next Safety now brings the same innovative approach to the science of pulmonary drug delivery and nicotine replacement.

For more information about Next Safety, Inc. visit www.nextsafety.com.

Contact

Next Safety, Inc.
Bethany Swaim, 336-246-7700


'"/>




Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
2. Bionovos MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
3. Oncolytics Biotech Inc.s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
4. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
5. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
6. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
7. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
8. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
9. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
10. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016   Bernstein Liebhard LLP today ... the United States District Court for the District of ... "Class") consisting of all persons or entities who purchased common ... INSY ) from March 3, 2015 through January 25, ... of its officers with violations of the Securities Exchange Act ...
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, ... much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on ... week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on ... Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for ... Furniture, lives with Parkinson’s disease and is the architect of this informative event to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... George H. Van Allen have signed a joint enrollment and degree completion agreement. ... pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows ...
(Date:2/5/2016)... ... 2016 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Event at the La Gorce Country Club in Miami Beach on March 15, ...
Breaking Medicine News(10 mins):